Compositions and methods for treating exocrine gland atrophy

US5639743A · kind A · utility

Assignees

• University of Georgia Research Foundation, Inc. · US
• University of Southern California · US

Inventors

• Renee Kaswan · Athens, US
• Austin K. Mircheff · La Cañada Flintridge, US
• Dwight W. Warren · San Fernando, US

Key dates

• Filing date: Jun 30, 1994
• Grant date: Jun 17, 1997
• Expiry date: Jun 30, 2014

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/2257
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and compositions for the prevention or reversal of exocrine gland atrophy, especially lacrimal gland atrophy, by maintaining normal physiological levels of prolactin are described. In the preferred embodiment, exogenous prolactin or a substance that modulates endogenous prolactin secretion is administered to a mammal in combination with an androgen, such as testosterone. The combination acts synergistically to maintain or restore normal prolactin concentrations, resulting in the maintenance or restoration of gland mass and function. Administration of prolactin and androgen in combination with estrogen is particularly useful in the treatment of lacrimal gland dysfunction in post-menopausal women or women who have undergone ovariohysterectomies.